Treatment Manages CMV in Transplant Recipients
Transpl Int. 2007; published online ahead of print
Preemptive ganciclovir treatment of cytomegalovirus (CMV) infection in simultaneous pancreas-kidney (SPK) transplant recipients appears to be associated with good long-term outcomes, German researchers report.
Nada Rayes, MD, and collaborators at Charité University Medicine
Symptomatic CMV infections oc-curred in 51% of patients and CMV syndrome occurred in 16%. In addition, 38% of patients with CMV infection experienced a recurrence, according to researchers. CMV had no impact on patient or graft survival, occurrence of acute or chronic rejection, and bacterial infections, the authors reported.